RECRUITING

Implementation of an Oral Chemotherapy Adherence Intervention

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural). The study will include 160 adult participants with either solid tumors or hematologic malignancies who have been taking oral anticancer agents for at least six months. This study will have two groups of participants, a pre- and post-implementation group. In the pre-implementation of the program group, investigators will administer a survey to the 80 participants and gather information about their medication prior to their enrollment of the program. Similarly, 80 participants who have been enrolled into this program for at least 6 months will serve as the post-implementation group. These patients will be administered the same survey. The results from both groups will be analyzed to see how effective the medication adherence program is.

Official Title

Design and Implementation of a Social Cognitive Theory-based Medication Adherence Intervention

Quick Facts

Study Start:2025-05-28
Study Completion:2028-08-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06989489

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult (age ≥21 years-old) patients
  2. * Diagnosed with a solid or hematologic malignancy
  3. * Monotherapy on oral anticancer agent on treatment for at least 6 months
  1. * Patients on time-limited or intermittent therapy (non-continuous)
  2. * Patients on comfort (end-of-life) care
  3. * Patients enrolled on hospice

Contacts and Locations

Study Contact

Solomon Ayehu, MD
CONTACT
9196722032
solsay@unc.edu
Bethel Belayneh
CONTACT
7039154836
bdbelay@ad.unc.edu

Principal Investigator

Benyam Muluneh, PharmD
PRINCIPAL_INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center

Study Locations (Sites)

UNC Chapel Hill
Chapel Hill, North Carolina, 27516
United States

Collaborators and Investigators

Sponsor: UNC Lineberger Comprehensive Cancer Center

  • Benyam Muluneh, PharmD, PRINCIPAL_INVESTIGATOR, UNC Lineberger Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-28
Study Completion Date2028-08-30

Study Record Updates

Study Start Date2025-05-28
Study Completion Date2028-08-30

Terms related to this study

Keywords Provided by Researchers

  • oral anticancer agent
  • oral chemotherapy
  • adherence

Additional Relevant MeSH Terms

  • Solid Tumor
  • Hematologic Malignancy